| 1/2 | US=22 / Urologia Cho D, Mier JW, Atkins MB. PI3K/AKt/mTOR pathway: a growth and proliferation pathway. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 267-85. ISBN 978-1-58829-737-2. INIBIDORES PI3K; RCC; HIPERATIVACAO DO AKT/PI3K; ATIVIDADE AKT; TEMSIROLIMUS |
| 2/2 | US=22-C / Câncer Copur MS, Gettinger SN, Goldberg SB, Deshpande HA. Agentes quimioterapêuticos variados. In: DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. 10 ed. Philadelphia: Wolters Kluwer, 2015. p. 267-277. ISBN 978-1-45119294-0. HOMOHARRINGTONINA E OMACETAXINA; L-ASPARAGINASE; BLEOMICINA; PROCARBAZINA; VISMODEGIB; ADO-TRASTUZUMAB EMTANSINE; SIROLIMUS E TEMSIROLIMUS; EVEROLIMUS; LENALIDOMIDA; TALIDOMIDA; POMALIDOMIDA |